Evidence map›Paper›PMID 29150208›Full record

ArticleVaccine2017

Development of a synthetic Vi polysaccharide vaccine for typhoid fever.

Yawei Ni, Michael J Springer, Jianhua Guo, Isaac Finger-Baker, James P Wilson, Ronald R Cobb, Debra Turner, Ian Tizard

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Travelers' Diarrhea: A Clinical Review.Recent patents on inflammation & allergy drug discovery · 2019
    Review
  5. Epidemiological and Clinical Features ofOman medical journal · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yawei NiResearch and Development, Nanotherapeutics, Inc., Alachua, FL, USA. Electronic address: yni@kjbiosciences.com.
Michael J SpringerResearch and Development, Nanotherapeutics, Inc., Alachua, FL, USA.
Jianhua GuoDepartment of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Isaac Finger-BakerResearch and Development, Nanotherapeutics, Inc., Alachua, FL, USA.
James P WilsonResearch and Development, Nanotherapeutics, Inc., Alachua, FL, USA.
Ronald R CobbResearch and Development, Nanotherapeutics, Inc., Alachua, FL, USA.
Debra TurnerDepartment of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Ian TizardDepartment of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Nanotherapeutics (United States) · USTexas A&M University · US

Funding

GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus VaccineR44AI094919 · NIAID · NANOTHERAPEUTICS, INC. · PI KIRK, JAMES FORREST, NI, YAWEI · 2011 to 2015
$3.6M
Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi VaccineR43AI081394 · NIAID · NANOTHERAPEUTICS, INC. · PI COBB, RONALD · 2010 to 2011
$596k
NIAID NIH HHS R43 AI081394NIAID NIH HHS R44 AI094919
6 · The paper itself

Abstract

Typhoid fever remains a serious public health problem with a high impact on toddlers and young children. Vaccines against the Vi capsular polysaccharide are efficacious against typhoid fever demonstrating that antibodies against Vi confer protection. The currently licensed Vi typhoid vaccines have however limited efficacy and are manufactured by a complex process from wild-type bacteria. Due to these inherent issues with the current vaccines, an alternative vaccine based on an O-acetylated high molecular weight (HMW) polygalacturonic acid (GelSite-OAc™) was generated. The HMW polygalacturonic acid shares the same backbone as the Vi polysaccharide of Salmonella Typhi. The GelSite-OAc™ has a high molecular weight (>1 × 10

Indexed as

AcetylationAnimalsAntibodies, BacterialAntibody FormationDisease Models, AnimalImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GImmunologic MemoryMicePectinsPolysaccharides, BacterialSalmonella typhiTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, SyntheticAntibodies, BacterialImmunoglobulin GPectinspolygalacturonic acidPolysaccharides, BacterialTyphoid-Paratyphoid VaccinesVaccines, SyntheticVi polysaccharide vaccine, typhoidAnimal modelO-acetylationPolygalacturonic acidSalmonella TyphiTyphoid feverVaccineVi polysaccharide

Identifiers

PMID29150208
PMCPMC5754192
OpenAlexW2769147175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.